Coccidioidomycosis: A regional disease of national importance: Rethinking approaches for control

Annals of Internal Medicine

Volumn 130, Issue 4 I, 1999, Pages 293-300

  Galgiani, John N ^a,b  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; FUNGUS VACCINE; ITRACONAZOLE; KETOCONAZOLE; NIKKOMYCIN;

COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; EARLY DIAGNOSIS; ENDEMIC DISEASE; FUNGAL GENETICS; HUMAN; INFECTION CONTROL; MEDICAL SPECIALIST; PNEUMONIA; PRIORITY JOURNAL; REVIEW; UNITED STATES;

EID: 0033573940     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-130-4-199902160-00015     Document Type: Review

References (129)

1. Rixford E. Case for diagnosis presented before the San Francisco Medico-Chirurgical Society, Mar. 5,1894. Occidental Medical Times. 1894;8:326.
2. Rixford E. A case of protozoic dermatitis. Occidental Medical Times. 1894; 8:704-7.
3. Ophuls W, Moffitt HC. A new pathogenic mould (formerly described as a protozoon: Coccidioides immitis pyogenes). preliminary report. Philadelphia Medical Journal. 1900;5:1471-2.
4. Gifford MA, Buss WC, Douds RJ, Miller HE, Tupper RB. Data on coccidioides fungus infection, Kern County. Kern County Department of Public Health Annual Report. 1936,39-54.
5. Edwards PQ, Palmer CE. Prevalence of sensitivity to coccidioidin, with special reference to specific and nonspecific reactions to coccidioidin and to histoplasmin. Dis Chest. 1957;31:35-60.
6. Palmer CE, Edwards PQ, Allfather WE. Characteristics of skin reactions to coccidioidin and histoplasmin, with evidence of an unidentified source of sensitivity in some geographic areas [Abstract]. Symposium on Coccidioidomycosis, Phoenix, Arizona. Atlanta: Communicable Disease Center; 1957: 171-80. PHS publication no. 575.
7. Smith CE, Saito MT, Simons SA. Pattern of 39,500 serologic tests in coccidioidomycosis. JAMA. 1956;160:546-52.
8. Smith CE. Diagnosis of pulmonary coccidioidal infections. California Medicine. 1951;75:385-91.
9. Smith CE, Saito MT, Beard RR, Kepp RM, Clark RW, Eddie BU. Serological tests in the diagnosis and prognosis of coccidioidomycosis. American Journal of Hygiene. 1950;52:1-21.
10. Smith CE, Beard RR, Saito MT. Pathogenesis of coccidioidomycosis with special reference to pulmonary cavitation. Ann Intern Med. 1948;29:623-55.
11. Smith CE. Coccidioidomycosis. Med Clin North Am. 1943,27:790-807.
12. Addressing emerging infectious disease threats: a prevention strategy for the United States. Atlanta: Centers for Disease Control and Prevention; 1994:1-46.
13. Kirkland TN, Fierer J. Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis. 1996;2:192-9.
14. Rutala PJ, Smith JW. Coccidioidomycosis in potentially compromised hosts: the effect of immunosuppressive therapy in dissemination. Am J Med Sci. 1978;275:283-95.
15. Deresinski SC, Stevens DA. Coccidioidomycosis in compromised hosts. Experience at Stanford University Hospital. Medicine (Baltimore). 1974;54: 377-95.
16. Hall KA, Sethi GK, Rosado LJ, Martinez JD, Huston CL, Copeland JG. Coccidioidomycosis and heart transplantation. J Heart Lung Transplant. 1993;12:525-6.
17. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med. 1982;142:489-94.
18. Holt CD, Winston DJ, Kubak B, Imagwa DK, Martin P, Goldstein L, et al. Coccidioidomycosis in liver transplant patients. Clin Infect Dis. 1997;24: 216-21.
19. Jones JL, Fleming PL, Ciesielski CA, Hu DJ, Kaplan JE, Ward JW. Coccidioidomycosis among persons with AIDS in the United States. J Infect Dis. 1995;171:961-6.
20. Ampel NM, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med. 1993;94:235-40.
21. Fish DG, Ampel NM, Galgiani JN, Dols CL, Kelly PC, Johnson CH, et al. Coccidioidomycosis during human immunodeficiency virus infection. A review of 77 patients. Medicine (Baltimore). 1990;69:384-91.
22. Singh VR, Smith DK, Lawerence J, Kelly PC, Thomas AR, Spitz B, et al. Coccidioidomycosis in patients infected with human immunodeficiency virus: review of 91 cases at a single institution. Clin Infect Dis. 1996;23: 563-8.
23. Hernández JL, Echevarría S, Garcia-Valtuille A, Mazorra F, Salesa R. Atypical coccidioidomycosis in an AIDS patient successfully treated with fluconazole. Eur J Clin Microbiol Infect Dis. 1997;16:592-4.
24. Vartivarian SE, Coudron PE, Markowitz SM. Disseminated coccidioidomycosis. Unusual manifestations in a cardiac transplantation patient. Am J Med. 1987;83:949-52.
25. Huppert M, Sun SH, Bailey JW. Natural variability in coccidioides immitis. In: Ajello L, ed. Coccidioidomycosis. The Second Symposium on Coccidioidomycosis. Tucson: Univ of Arizona Pr; 1965:323-8.
26. Koufopanou V, Burt A, Taylor JW. Concordance of gene genealogies reveals reproductive isolation in the pathogenic fungus Coccidioides immitis. Proc Natl Acad Sci U S A. 1997;94:5478-82.
27. Pappagianis D. Epidemiology of coccidioidomycosis. Curr Top Med Mycol. 1988;2:199-238.
28. Pappagianis D, Einstein H. Tempest from Tehachapi takes toll or Coccidioides conveyed aloft and afar. West J Med. 1978;129:527-30.
29. Smith CE, Beard RR, Rosenberger HG, Whiting EG. Effect of season and dust control on coccidioidomycosis. JAMA. 1946;132:833-8.
30. Schneider E, Hajjeh RA, Spiegel RA, Jibson RW, Harp EL, Marshall GA, et al. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA. 1997;277:904-8.
31. Pappagianis D. Marked increase in cases of coccidioidomycosis in California: 1991, 1992, and 1993. Clin Infect Dis. 1994;19 Suppl 1:514-8.
32. Coccidioidomycosis - United States, 1991-1992. MMWR Morb Mortal Wkly Rep. 1993;42:21-4.
33. Welch G, Jinadu BA, Talbot R. Geographic and epidemiologic characteristics of the 1991 coccidioidomycosis epidemic in Kern County California [Abstract]. Abstracts of the 120th Annual Meeting of the American Public Health Association. Washington, DC: American Public Health Association; 1992.
34. Stevens DA. Coccidioidomycosis. N Engl J Med. 1995;332:1077-82.
35. Kerrick SS, Lundergan LL, Galgiani JN. Coccidioidomycosis at a university health service. Am Rev Respir Dis. 1985;131:100-2.
36. Yozwiak ML, Lundergan LL, Kerrick SS, Galgiani JN. Symptoms and routine laboratory abnormalities associated with coccidioidomycosis. West J Med. 1988;149:419-21.
37. Wieden MA, Lundergan LL, Blum J, Delgado KL, Coolbaugh R, Howard R, et al. Detection of coccidioidal antibodies by 33-kDa spherule antigen, Coccidioides EIA, and standard serologic tests in sera from patients evaluated for coccidioidomycosis. J Infect Dis. 1996;173:1273-7.
38. Drutz DJ, Catanzaro A. Coccidioidomycosis Part II. Am Rev Respir Dis. 1978;117:727-71.
39. Standaert SM, Schaffner W, Galgiani JN, Pinner RW, Kaufman L, Durry E, et al. Coccidioidomycosis among vistors to a Coccidioides immitis-endemic area: an outbreak in a military reserve unit. J Infect Dis. 1995;171: 1672-5.
40. Cairns L, Blythe D, Kao A, et al. An outbreak of coccidioidomycosis in Washington State travelers returning from Mexico [Abstract]. Program and Abstracts - 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Thoracic Society for Microbiology, 1997.
41. Monheit JE, Cowan DF, Moore DG. Rapid detection of fungi in tissues using calcofluor white and fluorescence microscopy. Arch Pathol Lab Med. 1984;106:616-8.
42. Sobonya RE, Barbee RA, Wiens J, Trego D. Detection of fungi and other pathogens in immunocompromised patients by bronchoalveolar lavage in an area endemic for coccidioidomycosis. Chest. 1990;97:1349-55.
43. DiTomasso JP, Ampel NM, Sobonya RE, Bloom JW. Bronchoscopic diagnosis of pulmonary coccidioidomycosis. Comparison of cytology, culture, and transbronchial biopsy. Diagn Microbiol Infect Dis. 1994;18:83-7.
44. Sun SH, Huppert M, Vukovich KR. Rapid in vitro conversion and identification of Coccidioides immitis. J Clin Microbiol. 1976;3:186-90.
45. Huppert M, Sun SH, Rice EH. Specificity of exoantigens for identifying cultures of Coccidioides immitis. J Clin Microbiol. 1978;8:346-8.
46. Sandhu GS, Kline BC, Stockman L, Roberts GD. Molecular probes for diagnosis of fungal infections. J Clin Microbiol. 1995;33:2913-9.
47. Pappagianis D, Zimmer BL. Serology of coccidioidomycosis. Clin Microbiol Rev. 1990;3:247-68.
48. Martins TB, Jaskowski TD, Mouritsen CL, Hill HR. Comparison of commercially available enzyme immunoassay with traditional serological tests for detection of antibodies to Coccidioides immitis. J Clin Microbiol. 1995;33: 940-3.
49. Pappagianis D. Coccidioidomycosis. In: Balows A, Hausler WJ Jr, Lennette EH, eds. Laboratory Diagnosis of Infectious Diseases: Principles and Practice. Berlin: Springer-Verlag; 1988:600-23.
50. Zartarian M, Peterson EM, de la Maza LM. Detection of antibodies to Coccidioides immitis by enzyme immunoassay. Am J Clin Pathol. 1997;107: 148-53.
51. Riley DK, Galgiani JN, O'Donnell MR, Ito JI, Beatty PG, Evans TG. Coccidioidomycosis in bone marrow transplant recipients. Transplantation. 1994;56:1531-3.
52. Hall KA, Copeland JG, Zukoski CF, Sethi GK, Galgiani JN. Markers of coccidioidomycosis before cardiac or renal transplantation and the risk of recurrent infection. Transplantation. 1993;55:1422-4.
53. Huth RG. Concomitant systemic cryptococcosis and coccidioidomycosis in a patient with AIDS [Letter]. Clin Infect Dis. 1994;18:262-3.
54. Byrne WR, Dietrich RA. Disseminated coccidioidomycosis with peritonitis in a patient with acquired immunodeficiency syndrome. Prolonged survival associated with positive skin test reactivity to coccidioidin. Arch Intern Med. 1989;149:947-8.
55. Bronnimann DA, Adam RD, Galgiani JN, Habib MP, Petersen EA, Porter B, et al. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann Intern Med. 1987;106:372-9.
56. Ampel NM, Ryan KJ, Carry PJ, Wieden MA, Schifman RB. Fungemia due to Coccidioides immitis. An analysis of 16 episodes in 15 patients and a review of the literature. Medicine (Baltimore). 1986;65:312-21.
57. Walker MP, Brody CZ, Resnik R. Reactivation of coccidioidomycosis in pregnancy. Obstet Gynecol. 1992;79(5 Pt 2):815-7.
58. Peterson CM, Schuppert K, Kelly PC, Pappagianis D. Coccidioidomycosis and pregnancy. Obstet Gynecol Surv. 1993;48:149-56.
59. Pappagianis D, Lindsay S, Beall S, Williams P. Ethnic background and the clinical course of coccidioidomycosis [Letter]. Am Rev Respir Dis. 1979; 120:959-61.
60. Stadalnik RC, Goldstein E, Hoeprich PD, dos Santos PA, Lee KK. Diagnostic value of gallium and bone scans in evaluation of extrapulmonary coccidioidal lesions. Am Rev Respir Dis. 1980;121:673-6.
61. Boddicker JH, Fong D, Walsh TE, Schillaci RF, Moniot AL, Catanzaro A. Bone and gallium scanning in the evaluation of disseminated coccidioidomycosis. Am Rev Respir Dis. 1980;122:279-87.
62. Lund PJ, Chan KM, Unger EC, Galgiani JN, Pitt MJ. Magnetic resonance imaging in coccidioidal arthritis. Skeletal Radiol. 1996;25:661-5.
63. Stevens DA. Adequacy of therapy for coccidioidomycosis [Editorial]. Clin Infect Dis. 1997;25:1211-2.
64. Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, et al. Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124:305-10.
65. Catanzaro A, Galgiani JN, Levine BE, Sharley-Mathis PK, Fierer J, Stevens DA, et al. Fluconazole in the treatment of chronic pulmonary and nonmeningeal disseminated coccidioidomycosis. NIAID Mycoses Study Group. Am J Med. 1995;98:249-56.
66. Pérez JA Jr, Johnson RH, Caldwell JW, Arsura EL, Nemecheck P. Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med. 1995;155:1665-8.
67. Galgiani JN, Catanzaro A, Cloud GA, Higgs J, Friedman BA, Larsen RA, et al. Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med. 1993;119:28-35.
68. Stevens DA. Itraconazole and fluconazole for treatment of coccidioidomycosis [Letter]. Clin Infect Dis. 1994;18:470.
69. Diaz M, Puente R, de Hoyos LA, Cruz S. Itraconazole in the treatment of coccidioidomycosis. Chest. 1991;100:682-4.
70. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA. Itraconazole treatment of coccidioidomycosis. NIAID Mycoses Study Group. Am J Med. 1990;89:282-90.
71. Tucker RM, Denning DW, Dupont B, Stevens DA. Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med. 1990;112:108-12.
72. Galgiani JN, Stevens DA, Graybill JR, Dismukes WE, Cloud GA. Ketoconazole therapy of progressive coccidioidomycosis. Comparison of 400- and 800-mg doses and observations at higher doses. Am J Med. 1988;84: 603-10.
73. Drutz DJ. Ampnotericin B in the treatment of coccidioidomycosis Drugs. 1983;26:337-46.
74. Hardenbrook MH, Barriere SL. Coccidioidomycosis: evaluation of parameters used to predict outcome with amphotericin B therapy. Mycopathologia. 1982;78:65-71.
75. Erly WK, Carmody RF, Seeger JF, Lund PJ. Magnetic resonance imaging of coccidioidal spondylitis. International Journal of Neuroradiology. 1997;3: 385-92.
76. Galgiani JN. Coccidioidomycosis. In Remington JS, Schwartz MN, eds. Current Clinical Topics in Infectious Diseases. Boston: Blackwell Scientfic; 1997: 188-206.
77. Kushwaha VP, Shaw BA, Gerardi JA, Oppenheim WL. Musculoskeletal coccidioidomycosis. A review of 25 cases. Clin Orthop. 1996;332:190-9.
78. Einstein HE, Johnson RH. Coccidioidomycosis: new aspects of epidemiology and therapy. Clin Infect Dis. 1993;16:349-56.
79. Chang YC, Kwon-Chung KJ. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol. 1994;14:4912-9.
80. Kwon-Chung KJ, Edman JC, Wickes BL. Genetic association of mating types and virulence in Cryptococcus neoformans. Infect Immun. 1992;60: 602-5.
81. Torres-Guererro H, Edman JC. Melanin-deficient mutants of Cryptococcus neoformans. J Med Vet Mycol. 1994;32:303-13.
82. Lodge JK, Jackson-Machelski E, Toffaletti DL, Perfect JR, Gordon JI. Targeted gene replacement demonstrates that myristoyl-CoA: protein N-myristoyltransferase is essential for viability of Cryptococcus neoformans. Proc Natl Acad Sci U S A. 1994;91:12008-12.
83. Chang YC, Penoyer LA, Kwon-Chung KJ. The second capsule gene of Cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun. 1996;64:1977-83.
84. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, Williamson PR. Effect of the laccase gene, CNLAC1, on virulence of Cryptococcus neoformans. J Exp Med. 1996;184:377-86.
85. Chang YC, Cherniak R, Kozel TR, Granger DL, Morris LC, Weinhold LC, et al. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene. Infect Immun. 1997;65: 1584-92.
86. Woods JP, Goldman WE. In vivo generation of linear plasmids with addition of telomeric sequences by Histoplasma capsulatum. Mol Microbiol. 1992;6:3603-10.
87. Woods JP, Goldman WE. Autonomous replication of foreign DNA in Histoplasma capsulatum: role of native telomeric sequences. J Bacteriol. 1993; 175:636-41.
88. Worsham PL, Goldman WE. Development of a genetic transformation system for Histoplasma capsulatum: complementation of uracil auxotrophy. Mol Gen Genet. 1990;221:358-62.
89. Hogan LH, Klein BS. Transforming DNA integrates at multiple sites in the dimorphic fungal pathogen Blastomyces dermatitidis. Gene. 1997;186:219-26.
90. Beaman L, Pappagianis D, Benjamini E. Significance of T cells in resistance to experimental murine coccidioidomycosis. Infect Immun. 1977;17: 580-5.
91. Beaman L, Pappagianis D, Benjamini E. Mechanisms of resistance to infection with Coccidioides immitis in mice. Infect Immun. 1979;23:681-5.
92. Beaman L, Benjamini E, Pappagianis D. Role of lymphocytes in macrophage-induced killing of Coccidioides immitis in vitro. Infect Immun. 1981; 34:347-53.
93. Beaman L, Benjamini E, Pappagianis D. Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of Coccidioides immitis. Infect Immun. 1983;39:1201-7.
94. Beaman L. Fungicidal activation of murine macrophages by recombinant gamma interferon. Infect Immun. 1987;55:2951-5.
95. Beaman L. Effects of recombinant gamma interferon and tumor necrosis factor on in vitro interactions of human mononuclear phagocytes with Coccidioides immitis. Infect Immun. 1991;59:4227-9.
96. Magee DM, Cox RA. Roles of gamma interferon and interleukin-4 in genetically determined resistance to Coccidioides immitis. Infect Immun. 1995;63:3514-9.
97. Cox RA, Magee DM. Production of tumor necrosis factor alpha, interleukin-1 alpha, and interleukin-6 during murine coccidioidomycosis. Infect Immun. 1995;63:4178-80.
98. Magee DM, Cox RA. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun. 1996;64:3609-13.
99. Corry DB, Ampel NM, Christian L, Locksley RM, Galgiani JN. Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis. J Infect Dis. 1996;174:440-3.
100. Pappagianis D. Histopathologic response of mice to killed vaccines of Coccidioides immitis. J Invest Dermatol. 1967;49:71-7.
101. Huppert M, Levine HB, Sun SH, Peterson ET. Resistance of vaccinated mice to typical and atypical strains of Coccidioides immitis. J Bacteriol. 1967; 94:924-7.
102. Kong YM, Levine HB, Madin SH, Smith CE. Fungal multiplication and histopathologic changes in vaccinated mice infected with Coccidioides immitis. J Immunol. 1964;92:779-90.
103. Levine HB, Kong YC, Smith CE. Immunization of mice to Coccidioides immitis: dose, regimen and spherulation stage of killed spherule vaccines. J Immunol. 1965;94:132-42.
104. Levine HB, Miller RL, Smith CE. Influence of vaccination on respiratory coccidioidal disease in cynomolgus monkeys. J Immunol. 1962;89:242-51.
105. Levine HB, Cobb JM, Smith CE. Immunogenicity of spherule-endospore vaccines of Coccidioides immitis for mice. J Immunol. 1961;87:218-27.
106. Pappagianis D. Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group. Am Rev Respir Dis. 1993;148:656-60.
107. Zimmermann CR, Johnson SM, Martens GW, White AG, Zimmer BL, Pappagianis D. Protection against lethal murine coccidioidomycosis by a soluble vaccine from spherules. Infect Immun. 1998;66:2342-5.
108. Kirkland TN, Thomas PW, Finley F, Cole GT. Immunogenicity of a 48-kilodalton recombinant T-cell-reactive protein of Coccidioides immitis. Infect Immun. 1998;66:424-31.
109. Kirkland TN, Finley F, Orsborn KI, Galgiani JN. Evaluation of the prolinerich antigen of Coccidioides immitis as a vaccine candidate in mice. Infect Immun. 1998,66:3519-22.
110. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol. 1997;15:617-48.
111. Egeberg RO, Ely AF. Coccidioides immitis in the soil of the southern San Joaquin Valley. Am J Med Sci. 1956;23:151-4.
112. Elconin AF, Egeberg RO, Lubarsky R. Growth pattern of Coccidioides immitis in the soil of an endemic area. In: Proceedings of the Symposium on Coccidioidomycosis, Phoenix, AZ. Washington, DC: Public Health Service; 1957:168-70.
113. Elconin AF, Egeberg RO, Egeberg MC. Significance of soil salinity on the ecology of Coccidioides immitis. J Bacteriol. 1964;87:500-3.
114. Maddy KT. Ecological factors of the geographic distribution of Coccidioides immitis. J Am Vet Med Assoc. 1957;130:475-6.
115. Maddy KT. The geographic distribution of Coccidioides immitis and possible ecologic implications. Arizona Med. 1958;15:178-88.
116. Maddy KT, Crecelius HG, Cornell RG. Where can coccidioidomycosis be acquired in Arizona? Arizona Med. 1961;18:184-94.
117. Maddy KT. Observations on Coccidioides immitis found growing naturally in soil. Arizona Med. 1965;22:281-8.
118. Padhye AA, Smith G, Standard PG, McLaughlin D, Kaufman L. Comparative evaluation of chemiluminescent DNA probe assays and exoantigen tests for rapid identification of Blastomyces dermatitidis and Coccidioides immitis. J Clin Microbiol. 1994;32:867-70.
119. Stockman L, Clark KA, Hunt JM, Roberts GD. Evaluation of commercially available acridinium ester-labeled chemiluminescent DNA probes for culture identification of Blastomyces dermatitidis, Coccidioides immitis, Cryptococcus neoformans, and Histoplasma capsulatum. J Clin Microbiol. 1993;31: 845-50.
120. Bowman BH, Taylor JW, White TJ. Molecular evolution of the fungi: human pathogens. Mol Biol Evol. 1992;9:893-904.
121. Annual report: Top 100 drugs. Medical Advertising News. 1996;May:35.
122. Lutz JE, Clemens KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother. 1997;41:1558-61.
123. Schwartz S, Milatovic D, Thiel E. Successful treatment of cerebral aspergillosis with a novel triazole (voriconazole) in a patient with acute leukaemia. Br J Haematol. 1997;97:663-5.
124. Al-Abdely H, Revankar S, Graybill JR. Lipid formulations of amphotericin B. Seminars in Respiratory and Critical Care Medicine. 1997;18:289-99.
125. Clemons KV, Stevens DA. Comparative efficacy of amphotericin B colloidal dispersion and amphotericin B deoxycholate suspension in treatment of murine coccidioidomycosis. Antimicrob Agents Chemother. 1991;35:1829-33.
126. Hector RF, Zimmer BL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother. 1990;34:587-93.
127. Galgiani JN, Sun SH, Clemons KV, Stevens DA. Activity of cilofungin against Coccidioides immitis: differential in vitro effects on mycelia and spherules correlated with in vivo studies. J Infect Dis. 1990;162:944-8.
128. Levan NE. Workman's compensation legislation and coccidioidomycosis: legal and sociocultural considerations. In: Ajello L, ed. Coccidioidomycosis. Miami: Symposia Specialists, 1977:11-7.
129. Pappagianis D. Coccidioidomycosis (San Joaquin or Valley Fever). In: DiSalvo AF, ed. Occupational Mycoses. Philadelphia: Lea & Febiger; 1983:13-28.